Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance

Antiviral Research

Volumn 100, Issue 2, 2013, Pages 520-534

  Burnham, Andrew J ^a   Baranovich, Tatiana ^a   Govorkova, Elena A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Antiviral drug resistance; Influenza B virus; Neuraminidase inhibitors; Oseltamivir; Peramivir; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT; LANINAMIVIR; LANINAMIVIR OCTANOATE; MOLECULAR MARKER; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; NA PROTEIN, INFLUENZA B VIRUS; SIALIDASE; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DISEASE TRANSMISSION; HUMAN; IN VITRO STUDY; INFECTION RISK; INFECTION SENSITIVITY; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SEASONAL INFLUENZA; SINGLE DRUG DOSE; VIRUS MUTATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; INFLUENZA; NEURAMINIDASE INHIBITORS; VIROLOGY;

CERCOPITHECINE HERPESVIRUS 1; INFLUENZA A VIRUS; INFLUENZA B VIRUS;

ANTIVIRAL DRUG RESISTANCE; INFLUENZA B VIRUS; NEURAMINIDASE INHIBITORS; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

ANTIVIRAL AGENTS; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; VIRAL PROTEINS; ZANAMIVIR;

EID: 84885569081     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.08.023     Document Type: Review

References (158)

1. T. Aebi, M. Weisser, E. Bucher, H.H. Hirsch, S. Marsch, and M. Siegemund Co-infection of Influenza B and Streptococci causing severe pneumonia and septic shock in healthy women BMC Infect. Dis. 10 2010 308
2. G.M. Air Influenza neuraminidase Influenza Other Respir. Viruses 6 2012 245 256
3. F.Y. Aoki, G. Boivin, and N. Roberts Influenza virus susceptibility and resistance to oseltamivir Antiviral Ther. 12 2007 603 616
4. Y.S. Babu, P. Chand, S. Bantia, P. Kotian, A. Dehghani, Y. El-Kattan, T.H. Lin, T.L. Hutchison, A.J. Elliott, C.D. Parker, S.L. Ananth, L.L. Horn, G.W. Laver, and J.A. Montgomery BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design J. Med. Chem. 43 2000 3482 3486
5. S. Bantia, C.S. Arnold, C.D. Parker, R. Upshaw, and P. Chand Anti-influenza virus activity of peramivir in mice with single intramuscular injection Antiviral Res. 69 2006 39 45
6. J.M. Barnett, A. Cadman, F.M. Burrell, S.H. Madar, A.P. Lewis, M. Tisdale, and R. Bethell In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir Virology 265 1999 286 295
7. I.G. Barr, and L.L. Jelley The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs 72 2012 2177 2185
8. N. Bastien, J.B. Gubbay, D. Richardson, K. Sleeman, L. Gubareva, and Y. Li Detection of an influenza B virus strain with reduced susceptibility to neuraminidase inhibitor drugs J. Clin. Microbiol. 49 2011 4020 4021
9. E.Z. Baum, P.C. Wagaman, L. Ly, I. Turchi, J. Le, D. Bucher, and K. Bush A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding Antiviral Res. 59 2003 13 22
10. R.B. Belshe The need for quadrivalent vaccine against seasonal influenza Vaccine 28 Suppl. 4 2010 D45 D53
11. T. Betakova, M.V. Nermut, and A.J. Hay The NB protein is an integral component of the membrane of influenza B virus J. Gen. Virol. 77 Pt 11 1996 2689 2694
12. R. Bodewes, D. Morick, G. de Mutsert, N. Osinga, T. Bestebroer, S. van der Vliet, S.L. Smits, T. Kuiken, G.F. Rimmelzwaan, R.A. Fouchier, and A.D. Osterhaus Recurring influenza B virus infections in seals Emerg. Infect. Dis. 19 2013 511 512
13. W.P. Burmeister, R.W. Ruigrok, and S. Cusack The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid EMBO J. 11 1992 49 56
14. R.C. Buxton, B. Edwards, R.R. Juo, J.C. Voyta, M. Tisdale, and R.C. Bethell Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir Anal. Biochem. 280 2000 291 300
15. Y. Cardoso, E. Oliveira, J. Vasconcelos, A.L. Cohen, and M. Francisco Characteristics of patients with influenza-like illness, severe acture respiratory illness, and laboratory-confirmed influenza at a major children's hospital in Angola, 2009-2011 J. Infect. Dis. 206 Suppl 1 2012 S136 S139
16. S. Carr, N.A. Ilyushina, J. Franks, E.E. Adderson, M. Caniza, E.A. Govorkova, and R.G. Webster Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer Pediatr. Infect. Dis. J. 30 2011 284 288
17. R. Castillo, L.E. Holland, and D.A. Boltz Peramivir and its use in H1N1 influenza Drugs Today (Barc) 46 2010 399 408
18. CDC, 2013a. Influenza National and Regional Level Graphs and Data. Available from: < http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html >.
19. CDC, 2013b. Influenza-Associated Pediatric Mortality. Available from: < http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html >.
20. A.L. Cheam, I.G. Barr, A.W. Hampson, J. Mosse, and A.C. Hurt In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors Antiviral Res. 63 2004 177 181
21. J.M. Chen, Y.J. Guo, K.Y. Wu, J.F. Guo, M. Wang, J. Dong, Y. Zhang, Z. Li, and Y.L. Shu Exploration of the emergence of the Victoria lineage of influenza B virus Arch. Virol. 152 2007 415 422
22. R. Chen, and E.C. Holmes The evolutionary dynamics of human influenza B virus J. Mol. Evol. 66 2008 655 663
23. S.H. Chen, I.A. Huang, C.T. Wu, S.H. Hsia, P.C. Hung, and C.H. Chiu Complicated features in a young child with influenza B virus pneumonia and co-infection with Stenotrophomonas maltophilia Ann. Trop. Paediatr. 31 2011 159 162
24. W. Chen, Y. Zhong, Y. Qin, S. Sun, and Z. Li The evolutionary pattern of glycosylation sites in influenza virus (H5N1) hemagglutinin and neuraminidase PLoS ONE 7 2012 e49224
25. C.Y. Chi, S.M. Wang, C.C. Lin, H.C. Wang, J.R. Wang, I.J. Su, and C.C. Liu Clinical features of children infected with different strains of influenza B in southern Taiwan Pediatr. Infect. Dis. J. 27 2008 640 645
26. J.M. Colacino, W.G. Laver, and G.M. Air Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture J. Infect. Dis. 176 Suppl. 1 1997 S66 S68
27. P.M. Colman, J.N. Varghese, and W.G. Laver Structure of the catalytic and antigenic sites in influenza virus neuraminidase Nature 303 1983 41 44
28. P.M. Colman, P.A. Hoyne, and M.C. Lawrence Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase J. Virol. 67 1993 2972 2980
29. P.M. Colman Influenza virus neuraminidase: structure, antibodies, and inhibitors Protein Sci. 3 1994 1687 1696
30. N.J. Cooper, A.J. Sutton, K.R. Abrams, A. Wailoo, D. Turner, and K.G. Nicholson Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials BMJ 326 2003 1235
31. R.D. Craver, K. Sorrells, and R. Gohd Myocarditis with influenza B infection Pediatr. Infect. Dis. J. 16 1997 629 630
32. W.L. Davies, R.R. Grunert, R.F. Haff, J.W. McGahen, E.M. Neumayer, M. Paulshock, J.C. Watts, T.R. Wood, E.C. Hermann, and C.E. Hoffmann Antiviral activity of 1-adamantanamine (Amantadine) Science 144 1964 862 863
33. V.M. Deyde, T.G. Sheu, A.A. Trujillo, M. Okomo-Adhiambo, R. Garten, A.I. Klimov, and L.V. Gubareva Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing Antimicrob. Agents Chemother. 54 2010 1102 1110
34. M.H. Ebell, M. Call, and J. Shinholser Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials Fam. Pract. 30 2013 125 133
35. V. Escuret, E. Frobert, M. Bouscambert-Duchamp, M. Sabatier, I. Grog, M. Valette, B. Lina, F. Morfin, and O. Ferraris Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors J. Clin. Virol. 41 2008 25 28
36. EuroFlu, 2013. EuroFlu Electronic Bulletin. Available from: < http://www.euroflu.org >.
37. FDA, 2013a. Approved Products - Fluzone Quadrivalent. Available from: < http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ ucm356091.htm >.
38. FDA, 2013b. Approved Products - FluMist Quadrivalent. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm293952. htm.
39. FDA, 2013c. Approved Products - Fluarix Quadrivalent. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm342391. htm.
40. T. Francis Jr. A new type of virus from epidemic influenza Science 92 1940 405 408
41. H. Frank, C. Wittekind, U.G. Liebert, M. Siekmeyer, W. Siekmeyer, V. Schuster, and W. Kiess Lethal influenza B myocarditis in a child and review of the literature for pediatric age groups Infection 38 2010 231 235
42. S. Fujisaki, E. Takashita, M. Yokoyama, T. Taniwaki, H. Xu, N. Kishida, H. Sato, M. Tashiro, M. Imai, and T. Odagiri A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs Biochem. Biophys. Res. Commun. 429 2012 51 56
43. S. Garg, Z. Moore, N. Lee, J. McKenna, A. Bishop, A. Fleischauer, C.B. Springs, H.T. Nguyen, T.G. Sheu, K. Sleeman, L. Finelli, L. Gubareva, and A.M. Fry A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility-North Carolina and South Carolina, 2010-2011 J. Infect. Dis. 207 2013 966 973
44. Genentech USA, I., 2012. Tamiflu® (oseltamivir phosphate) Prescribing Information. In: Genentech (Ed.), South San Francisco, CA.
45. GlaxoSmithKline, 2013. Relenza (Zanamivir for Inhalation) prescribing information, us.gsk.com/products/assets/us-relenza.pdf
46. W.P. Glezen, J.K. Schmier, C.M. Kuehn, K.J. Ryan, and J. Oxford The burden of influenza B: a structured literature review Am. J. Public Health 103 2013 e43 e51
47. R. Guan, L.C. Ma, P.G. Leonard, B.R. Amer, H. Sridharan, C. Zhao, R.M. Krug, and G.T. Montelione Structural basis for the sequence-specific recognition of human ISG15 by the NS1 protein of influenza B virus Proc. Natl. Acad. Sci. USA 108 2011 13468 13473
48. L.V. Gubareva, M.N. Matrosovich, M.K. Brenner, R.C. Bethell, and R.G. Webster Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus J. Infect. Dis. 178 1998 1257 1262
49. A. Gutierrez-Pizarraya, P. Perez-Romero, R. Alvarez, T.A. Aydillo, G. Osorio-Gomez, C. Milara-Ibanez, M. Sanchez, J. Pachon, and E. Cordero Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave J. Infect. 65 2012 423 430
50. S.A. Harper, J.S. Bradley, J.A. Englund, T.M. File, S. Gravenstein, F.G. Hayden, A.J. McGeer, K.M. Neuzil, A.T. Pavia, M.L. Tapper, T.M. Uyeki, and R.K. Zimmerman Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America Clin. Infect. Dis. 48 2009 1003 1032
51. S. Hatakeyama, N. Sugaya, M. Ito, M. Yamazaki, M. Ichikawa, K. Kimura, M. Kiso, H. Shimizu, C. Kawakami, K. Koike, K. Mitamura, and Y. Kawaoka Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors JAMA 297 2007 1435 1442
52. S. Hatakeyama, M. Ozawa, and Y. Kawaoka In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors Clin. Microbiol. Infect. 17 2011 1332 1335
53. M. Hatta, and Y. Kawaoka The NB protein of influenza B virus is not necessary for virus replication in vitro J. Virol. 77 2003 6050 6054
54. A.J. Hay, V. Gregory, A.R. Douglas, and Y.P. Lin The evolution of human influenza viruses Philos. Trans. R. Soc. Lond. B Biol. Sci. 356 2001 1861 1870
55. F.G. Hayden, A.D. Osterhaus, J.J. Treanor, D.M. Fleming, F.Y. Aoki, K.G. Nicholson, A.M. Bohnen, H.M. Hirst, O. Keene, and K. Wightman Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group N. Engl. J. Med. 337 1997 874 880
56. F.G. Hayden, R.L. Atmar, M. Schilling, C. Johnson, D. Poretz, D. Paar, L. Huson, P. Ward, and R.G. Mills Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza N. Engl. J. Med. 341 1999 1336 1343
57. F.G. Hayden, J.J. Treanor, R.S. Fritz, M. Lobo, R.F. Betts, M. Miller, N. Kinnersley, R.G. Mills, P. Ward, and S.E. Straus Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment JAMA 282 1999 1240 1246
58. F.G. Hayden, L. Jennings, R. Robson, G. Schiff, H. Jackson, B. Rana, G. McClelland, D. Ipe, N. Roberts, and P. Ward Oral oseltamivir in human experimental influenza B infection Antiviral Ther. 5 2000 205 213
59. G. He, J. Massarella, and P. Ward Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802 Clin. Pharmacokinet. 37 1999 471 484
60. S. Heinonen, H. Silvennoinen, P. Lehtinen, R. Vainionpaa, T. Vahlberg, T. Ziegler, N. Ikonen, T. Puhakka, and T. Heikkinen Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial Clin. Infect. Dis. 51 2010 887 894
61. R.R. Higgins, M. Beniprashad, E. Chong-King, Y. Li, N. Bastien, D.E. Low, and J.B. Gubbay Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient J. Clin. Microbiol. 50 2012 2500 2502
62. T. Hikita, H. Hikita, F. Hikita, N. Hikita, and S. Hikita Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients Int. J. Pediatr. 2012 2012 834181
63. Hoffmann-La Roche, I., Nutley, New Jersey, 2007. Pediatric Advisory Committee Breifing Document for Tamiflu. Available from: < http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4325b-02-15- Sponsor%20Background%20Package%20Roche.pdf >.
64. F.L. Horsfall, R.G. Hahn, and E.R. Rickard Four recent influenza epidemics: an experimental study J. Clin. Invest. 19 1940 379 392
65. A.C. Hurt, I.G. Barr, G. Hartel, and A.W. Hampson Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir Antiviral Res. 62 2004 37 45
66. A.C. Hurt, J.L. McKimm-Breschkin, M. McDonald, I.G. Barr, N. Komadina, and A.W. Hampson Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs Virus Res. 103 2004 205 211
67. A.C. Hurt, P. Iannello, K. Jachno, N. Komadina, A.W. Hampson, I.G. Barr, and J.L. McKimm-Breschkin Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient Antimicrob. Agents Chemother. 50 2006 1872 1874
68. H. Ishizuka, S. Yoshiba, H. Okabe, and K. Yoshihara Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers J. Clin. Pharmacol. 50 2010 1319 1329
69. M.G. Ison, L.V. Gubareva, R.L. Atmar, J. Treanor, and F.G. Hayden Recovery of drug-resistant influenza virus from immunocompromised patients: a case series J. Infect. Dis. 193 2006 760 764
70. D. Jackson, W. Barclay, and T. Zurcher Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations J. Antimicrob. Chemother. 55 2005 162 169
71. D. Jackson, R.A. Elderfield, and W.S. Barclay Molecular studies of influenza B virus in the reverse genetics era J. Gen. Virol. 92 2011 1 17
72. Jefferson, T., Jones, M.A., Doshi, P., Del Mar, C.B., Heneghan, C.J., Hama, R., Thompson, M.J., 2012. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. The, Cochrane database of systematic reviews 1, CD008965.
73. N. Kawai, H. Ikematsu, N. Iwaki, T. Maeda, I. Satoh, N. Hirotsu, and S. Kashiwagi A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons Clin. Infect. Dis. 43 2006 439 444
74. N. Kawai, H. Ikematsu, N. Iwaki, T. Kawashima, T. Maeda, S. Mitsuoka, K. Kondou, I. Satoh, K. Miyachi, S. Yamaga, T. Shigematsu, N. Hirotsu, and S. Kashiwagi Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir J. Infect. 55 2007 267 272
75. N. Kawai, H. Ikematsu, N. Iwaki, T. Maeda, H. Kanazawa, T. Kawashima, O. Tanaka, S. Yamauchi, K. Kawamura, T. Nagai, S. Horii, N. Hirotsu, and S. Kashiwagi A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B J. Infect. 56 2008 51 57
76. Y.H. Kim, H.S. Kim, S.H. Cho, and S.H. Seo Influenza B virus causes milder pathogenesis and weaker inflammatory responses in ferrets than influenza A virus Viral Immunol. 22 2009 423 430
77. M. Kitano, Y. Itoh, M. Kodama, H. Ishigaki, M. Nakayama, H. Ishida, K. Baba, T. Noda, K. Sato, Y. Nihashi, T. Kanazu, R. Yoshida, R. Torii, A. Sato, and K. Ogasawara Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques Antimicrob. Agents Chemother. 55 2011 4961 4970
78. A.I. Klimov, E. Rocha, F.G. Hayden, P.A. Shult, L.F. Roumillat, and N.J. Cox Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis J. Infect. Dis. 172 1995 1352 1355
79. S. Krell, I. Adams, U. Arnold, T. Kalinski, V. Aumann, W. Konig, and B. Konig Influenza B pneumonia with Staphylococcus aureus superinfection associated with parvovirus B19 and concomitant agranulocytosis Infection 31 2003 353 358
80. S. Kubo, A. Tokumitsu, T. Tomozawa, M. Kakuta, and M. Yamashita High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals J. Infect. Chemother. 18 2012 69 74
81. S. Li, J. Schulman, S. Itamura, and P. Palese Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus J. Virol. 67 1993 6667 6673
82. W.C. Li, S.R. Shih, Y.C. Huang, G.W. Chen, S.C. Chang, M.J. Hsiao, K.C. Tsao, and T.Y. Lin Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan J. Clin. Virol. 42 2008 45 51
83. K.C. Lu, P.Y. Chen, F.L. Huang, H.W. Yu, C.H. Kao, and Y.J. Lau Influenza B virus associated pneumonia: report of one case Acta Paediatr. Taiwan 45 2004 242 245
84. Y. Matsuzaki, K. Sugawara, E. Takashita, Y. Muraki, S. Hongo, N. Katsushima, K. Mizuta, and H. Nishimura Genetic diversity of influenza B virus: the frequent reassortment and cocirculation of the genetically distinct reassortant viruses in a community J. Med. Virol. 74 2004 132 140
85. J.A. McCullers, T. Saito, and A.R. Iverson Multiple genotypes of influenza B virus circulated between 1979 and 2003 J. Virol. 78 2004 12817 12828
86. J.A. McCullers, E. Hoffmann, V.C. Huber, and A.D. Nickerson A single amino acid change in the C-terminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and virulence Virology 336 2005 318 326
87. J.A. McCullers, and F.G. Hayden Fatal influenza B infections: time to reexamine influenza research priorities J. Infect. Dis. 205 2012 870 872
88. J. McKimm-Breschkin, T. Trivedi, A. Hampson, A. Hay, A. Klimov, M. Tashiro, F. Hayden, and M. Zambon Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir Antimicrob. Agents Chemother. 47 2003 2264 2272
89. B. Michiels, K. Van Puyenbroeck, V. Verhoeven, E. Vermeire, and S. Coenen The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews PLoS ONE 8 2013 e60348
90. V.P. Mishin, F.G. Hayden, and L.V. Gubareva Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors Antimicrob. Agents Chemother. 49 2005 4515 4520
91. A.S. Monto, D.P. Robinson, M.L. Herlocher, J.M. Hinson Jr., M.J. Elliott, and A. Crisp Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial JAMA 282 1999 31 35
92. A.S. Monto, J.L. McKimm-Breschkin, C. Macken, A.W. Hampson, A. Hay, A. Klimov, M. Tashiro, R.G. Webster, M. Aymard, F.G. Hayden, and M. Zambon Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use Antimicrob. Agents Chemother. 50 2006 2395 2402
93. J. Muneuchi, Y. Kanaya, T. Takimoto, T. Hoshina, K. Kusuhara, and T. Hara Myocarditis mimicking acute coronary syndrome following influenza B virus infection: a case report Cases J. 2 2009 6809
94. S.A. Namendys-Silva, M.O. Gonzalez-Herrera, J. Texcocano-Becerra, and A. Herrera-Gomez Acute respiratory distress syndrome caused by influenza B virus infection in a patient with diffuse large B-cell lymphoma Case Rep. Med. 2011 2011 647528
95. J.G. Newland, J.R. Romero, M. Varman, C. Drake, A. Holst, T. Safranek, and K. Subbarao Encephalitis associated with influenza B virus infection in 2 children and a review of the literature Clin. Infect. Dis. 36 2003 e87 e95
96. H.T. Nguyen, A.M. Fry, and L.V. Gubareva Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods Antiviral Ther. 17 2012 159 173
97. H.T. Nguyen, A.A. Trujillo, T.G. Sheu, M. Levine, V.P. Mishin, M. Shaw, E.W. Ades, A.I. Klimov, A.M. Fry, and L.V. Gubareva Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States Antiviral Res. 93 2012 381 386
98. K.G. Nicholson, F.Y. Aoki, A.D. Osterhaus, S. Trottier, O. Carewicz, C.H. Mercier, A. Rode, N. Kinnersley, and P. Ward Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group Lancet 355 2000 1845 1850
99. NIID, 2013. Flash report of influenza virus. Available from: < http://www.nih.go.jp/niid/en/iasr-inf-e.html >.
100. NIMR, 2013. WHO Influenza Centre - Annual and interim reports | MRC National Institute for Medical Research, London. Available from: < http://www.nimr.mrc.ac.uk/who-influenza-centre/annual-and-interim-reports/ >.
101. E. Nobusawa, and K. Sato Comparison of the mutation rates of human influenza A and B viruses J. Virol. 80 2006 3675 3678
102. A.J. Oakley, S. Barrett, T.S. Peat, J. Newman, V.A. Streltsov, L. Waddington, T. Saito, M. Tashiro, and J.L. McKimm-Breschkin Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses J. Med. Chem. 53 2010 6421 6431
103. K. Ohishi, A. Ninomiya, H. Kida, C.H. Park, T. Maruyama, T. Arai, E. Katsumata, T. Tobayama, A.N. Boltunov, L.S. Khuraskin, and N. Miyazaki Serological evidence of transmission of human influenza A and B viruses to Caspian seals (Phoca caspica) Microbiol. Immunol. 46 2002 639 644
104. M. Okomo-Adhiambo, K. Sleeman, K. Ballenger, H.T. Nguyen, V.P. Mishin, T.G. Sheu, J. Smagala, Y. Li, A.I. Klimov, and L.V. Gubareva Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective Viruses 2 2010 2269 2289
105. Okomo-Adhiambo, M., Sleeman, K., Lysen, C., Nguyen, H.T., Xu, X., Li, Y., Klimov, A.I., Gubareva, L.V., 2013. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza and other respiratory viruses.
106. A.D. Osterhaus, G.F. Rimmelzwaan, B.E. Martina, T.M. Bestebroer, and R.A. Fouchier Influenza B virus in seals Science 288 2000 1051 1053
107. C.D. Paddock, L. Liu, A.M. Denison, J.H. Bartlett, R.C. Holman, M. Deleon-Carnes, S.L. Emery, C.P. Drew, W.J. Shieh, T.M. Uyeki, and S.R. Zaki Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection J. Infect. Dis. 205 2012 895 905
108. V. Peltola, T. Ziegler, and O. Ruuskanen Influenza A and B virus infections in children Clin. Infect. Dis. 36 2003 299 305
109. V. Peltola, O. Ruuskanen, and T. Heikkinen Targeting influenza vaccinations of children CMAJ 183 2011 1464 1465
110. N. Pica, Y.Y. Chou, N.M. Bouvier, and P. Palese Transmission of influenza B viruses in the guinea pig J. Virol. 86 2012 4279 4287
111. M. Potier, L. Mameli, M. Belisle, L. Dallaire, and S.B. Melancon Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d- N-acetylneuraminate) substrate Anal. Biochem. 94 1979 287 296
112. F. Pozo, B. Lina, H.R. Andrade, V. Enouf, A. Kossyvakis, E. Broberg, R. Daniels, A. Lackenby, and A. Meijer Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe J. Clin. Virol. 57 2013 5 12
113. S. Puzelli, F. Frezza, C. Fabiani, F. Ansaldi, L. Campitelli, Y.P. Lin, V. Gregory, M. Bennett, P. D'Agaro, C. Campello, P. Crovari, A. Hay, and I. Donatelli Changes in the hemagglutinins and neuraminidases of human influenza B viruses isolated in Italy during the 2001-02, 2002-03, and 2003-04 seasons J. Med. Virol. 74 2004 629 640
114. C. Reed, M.I. Meltzer, L. Finelli, and A. Fiore Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine Vaccine 30 2012 1993 1998
115. P.A. Rota, M.L. Hemphill, T. Whistler, H.L. Regnery, and A.P. Kendal Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus J. Gen. Virol. 73 Pt 10 1992 2737 2742
116. T. Roy, A.S. Agrawal, A. Mukherjee, A.C. Mishra, M.S. Chadha, H. Kaur, and M. Chawla-Sarkar Surveillance and molecular characterization of human influenza B viruses during 2006-2010 revealed co-circulation of Yamagata-like and Victoria-like strains in eastern India Infect. Genet. Evol. 11 2011 1595 1601
117. R.J. Russell, L.F. Haire, D.J. Stevens, P.J. Collins, Y.P. Lin, G.M. Blackburn, A.J. Hay, S.J. Gamblin, and J.J. Skehel The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design Nature 443 2006 45 49
118. T. Saito, and K. Kawano Loss of glycosylation at Asn144 alters the substrate preference of the N8 influenza A virus neuraminidase J. Vet. Med. Sci. 59 1997 923 926
119. M. Samson, A. Pizzorno, Y. Abed, and G. Boivin Influenza virus resistance to neuraminidase inhibitors Antiviral Res. 98 2013 174 185
120. M. Sato, R. Saito, I. Sato, N. Tanabe, Y. Shobugawa, A. Sasaki, D. Li, Y. Suzuki, T. Sakai, T. Oguma, H. Tsukada, F. Gejyo, and H. Suzuki Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan Tohoku J. Exp. Med. 214 2008 113 120
121. M.W. Shaw, X. Xu, Y. Li, S. Normand, R.T. Ueki, G.Y. Kunimoto, H. Hall, A. Klimov, N.J. Cox, and K. Subbarao Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons Virology 303 2002 1 8
122. A.K. Shetty, and L.A. Peek Peramivir for the treatment of influenza Expert. Rev. Anti. Infect. Ther. 10 2012 123 143
123. T.G. Sheu, V.M. Deyde, M. Okomo-Adhiambo, R.J. Garten, X. Xu, R.A. Bright, E.N. Butler, T.R. Wallis, A.I. Klimov, and L.V. Gubareva Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008 Antimicrob. Agents Chemother. 52 2008 3284 3292
124. T.G. Sheu, V.M. Deyde, R.J. Garten, A.I. Klimov, and L.V. Gubareva Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing Antiviral Res. 85 2010 354 360
125. R.W. Sidwell, D.F. Smee, J.H. Huffman, D.L. Barnard, K.W. Bailey, J.D. Morrey, and Y.S. Babu In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201 Antimicrob. Agents Chemother. 45 2001 749 757
126. K. Sleeman, T.G. Sheu, Z. Moore, S. Kilpatrick, S. Garg, A.M. Fry, and L.V. Gubareva Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11 Emerg. Infect. Dis. 17 2011 2043 2046
127. K.A. Staschke, J.M. Colacino, A.J. Baxter, G.M. Air, A. Bansal, W.J. Hornback, J.E. Munroe, and W.G. Laver Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en Virology 214 1995 642 646
128. M.Y. Stoeckle, M.W. Shaw, and P.W. Choppin Segment-specific and common nucleotide sequences in the noncoding regions of influenza B virus genome RNAs Proc. Natl. Acad. Sci. USA 84 1987 2703 2707
129. N. Sugaya, K. Mitamura, M. Yamazaki, D. Tamura, M. Ichikawa, K. Kimura, C. Kawakami, M. Kiso, M. Ito, S. Hatakeyama, and Y. Kawaoka Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children Clin. Infect. Dis. 44 2007 197 202
130. N. Sugaya, D. Tamura, M. Yamazaki, M. Ichikawa, C. Kawakami, Y. Kawaoka, and K. Mitamura Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children Clin. Infect. Dis. 47 2008 339 345
131. N. Sugaya, and Y. Ohashi Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection Antimicrob. Agents Chemother. 54 2010 2575 2582
132. N. Sugaya, S. Kohno, T. Ishibashi, T. Wajima, and T. Takahashi Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection Antimicrob. Agents Chemother. 56 2012 369 377
133. N.A. Sunstrom, L.S. Premkumar, A. Premkumar, G. Ewart, G.B. Cox, and P.W. Gage Ion channels formed by NB, an influenza B virus protein J. Membr. Biol. 150 1996 127 132
134. S. Tabbutt, M. Leonard, R.I. Godinez, M. Sebert, J. Cullen, T.L. Spray, and D. Friedman Severe influenza B myocarditis and myositis Pediatr. Crit. Care Med. 5 2004 403 406
135. M. Tashiro, J.L. McKimm-Breschkin, T. Saito, A. Klimov, C. Macken, M. Zambon, and F.G. Hayden Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007 Antiviral Ther. 14 2009 751 761
136. N.R. Taylor, A. Cleasby, O. Singh, T. Skarzynski, A.J. Wonacott, P.W. Smith, S.L. Sollis, P.D. Howes, P.C. Cherry, R. Bethell, P. Colman, and J. Varghese Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B J. Med. Chem. 41 1998 798 807
137. W.W. Thompson, D.K. Shay, E. Weintraub, L. Brammer, N. Cox, L.J. Anderson, and K. Fukuda Mortality associated with influenza and respiratory syncytial virus in the United States JAMA 289 2003 179 186
138. J.J. Treanor, F.G. Hayden, P.S. Vrooman, R. Barbarash, R. Bettis, D. Riff, S. Singh, N. Kinnersley, P. Ward, and R.G. Mills Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group JAMA 283 2000 1016 1024
139. J.N. Varghese, J.L. McKimm-Breschkin, J.B. Caldwell, A.A. Kortt, and P.M. Colman The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor Proteins 14 1992 327 332
140. M. von Itzstein, W.Y. Wu, G.B. Kok, M.S. Pegg, J.C. Dyason, B. Jin, T. Van Phan, M.L. Smythe, H.F. White, and S.W. Oliver Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 363 1993 418 423
141. C.C. Wang, P.Y. Chen, J.D. Wang, F.C. Liu, F.L. Huang, and C.Y. Lee Clinical and laboratory analysis of influenza B infection in children in Taichung, Taiwan during the 2006-2007 flu season Pediatr. Neonatol. 50 2009 54 58
142. D. Wang, K. Sleeman, W. Huang, H.T. Nguyen, M. Levine, Y. Cheng, X. Li, M. Tan, X. Xing, X. Xu, A.I. Klimov, L.V. Gubareva, and Y. Shu Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir Antiviral Res. 97 2013 240 244
143. Wang, K., Shun-Shin, M., Gill, P., Perera, R., Harnden, A., 2012. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). The, Cochrane database of systematic reviews 4, CD002744.
144. A. Watanabe, S.C. Chang, M.J. Kim, D.W. Chu, and Y. Ohashi Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial Clin. Infect. Dis. 51 2010 1167 1175
145. N.T. Wetherall, T. Trivedi, J. Zeller, C. Hodges-Savola, J.L. McKimm-Breschkin, M. Zambon, and F.G. Hayden Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network J. Clin. Microbiol. 41 2003 742 750
146. R.J. Whitley, F.G. Hayden, K.S. Reisinger, N. Young, R. Dutkowski, D. Ipe, R.G. Mills, and P. Ward Oral oseltamivir treatment of influenza in children Pediatr. Infect. Dis. J. 20 2001 127 133
147. R.J. Whitley, C.A. Boucher, B. Lina, J.S. Nguyen-Van-Tam, A. Osterhaus, M. Schutten, and A.S. Monto Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS) Clin. Infect. Dis. 56 2013 1197 1205
148. WHO Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons Wkly Epidemiol. Rec. 82 2007 149 150
149. WHO Review of the 2010-2011 winter influenza season, northern hemisphere Wkly Epidemiol. Rec. 86 2011 222 227
150. WHO, 2012a. WHO information for molecular diagnosis of influenza virus in humans - update. Available from: http://www.who.int/influenza/gisrs-laboratory/ molecular-diagnosis/en/.
151. WHO, 2012b. Antiviral-resistant B viruses with a novel mutation detected by antiviral resistance surveillance in Japan. Available from: < http://www.wpro.who.int/emerging-diseases/meetings/docs/ AntiviralResistantBVirusesinJapan.pdf >.
152. WHO Recommended composition of influenza virus vaccines for use in the 2013-2014 northern hemisphere influenza season Wkly Epidemiol. Rec. 88 2013 101 114
153. P.F. Wright The use of inactivated influenza vaccine in children Semin. Pediatr. Infect. Dis. 17 2006 200 205
154. P.F. Wright, G. Neumann, and Y. Kawaoka Orthomyxoviruses P.H. David Knipe, Fields Virology fifth ed. 2006 Lippincott Williams & Wilkins 1691 1740
155. M. Yamashita, M. Krystal, W.M. Fitch, and P. Palese Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses Virology 163 1988 112 122
156. M. Yamashita, T. Tomozawa, M. Kakuta, A. Tokumitsu, H. Nasu, and S. Kubo CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity Antimicrob. Agents Chemother. 53 2009 186 192
157. K. Yusuf, A.S. Soraisham, and K. Fonseca Fatal influenza B virus pneumonia in a preterm neonate: case report and review of the literature J. Perinatol. 27 2007 623 625
158. M. Zambon, and F.G. Hayden Position statement: global neuraminidase inhibitor susceptibility network Antiviral Res. 49 2001 147 156